cyrilzakka/clinical-trials huggingface dataset:
A Study of Baked Milk Tolerance to Treat Eosinophilic Esophagtis

This research is being done to see if patients with milk-triggered EoE are able to tolerate baked milk in their diet and if there is a threshold amount of straight milk that is tolerable.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with Eosinophilic esophagitis ≥ 15 eosinophils per HPF
* Going through or completed the six-food elimination diet, with milk only or milk plus one additional food identified as a trigger

Exclusion Criteria:

* Patients with conditions known to be associated with esophageal eosinophilia, including Crohn's disease, Churg-Strauss, achalasia, and hypereosinophilic syndrome
* Topical swallowed steroids within 8 weeks of study enrollment
* Inability to read due to: Blindness, cognitive dysfunction, or English language illiteracy
Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients

The purpose of this study is to evaluate the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients.

Not provided

Eligibility Criteria:
Inclusion Criteria:

* Pediatric patients affected by any type of SCID confirmed by clinical, immunological and/or molecular diagnosis and eligible for an allogeneic HSCT
* Absence of a matched sibling donor or a matched unrelated donor (MUD) 10/10
* Clinical conditions incompatible with the search of a MUD
* Written, informed consent of parents/ legal representative (child)
* Age ≤ 2 years at the time of screening
* No prior therapy with allogeneic stem cell transplantation
* No treatment with another investigational drug within one month before inclusion
* Patient affiliated to social security

Exclusion Criteria:

* Presence of an HLA genoidentical donor
* Absence of written parental consent
* Treatment with another investigational drug within one month before inclusion
* Positive for HIV infection by genome PCR
* Contra-indication to allogeneic transplantation or conditioning therapy (except SCID patients with DNA repair deficiency)
Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

The purpose of this study is to see if emtricitabine is safe in children infected with HIV and to determine the best dose.

Children are placed into 1 of 4 treatment groups based on age: Group 1, 3 months to 24 months; Group 2, 25 months to 6 years; Group 3, 7 years to 12 years; Group 4, 13 years to 17 years. They receive baseline evaluations. Antiretroviral-naive patients receive emtricitabine plus stavudine plus lopinavir/ritonavir. Antiretroviral-experienced patients replace lamivudine with emtricitabine. Patients return to the clinic for follow-up visits at Weeks 2 and 4 and then every 4 weeks until Week 48. Safety is evaluated using adverse events, which are reviewed at every clinic visit. Clinical laboratory data and full-profile pharmacokinetics of emtricitabine are evaluated at some visits. After the Week 48 study evaluations are completed, individual patients may continue to receive study medication (as provided by the sponsor) until commercially available, if certain criteria are met.

Eligibility Criteria:
Inclusion Criteria

Children may be eligible for this study if they:

* Are at least 3 months old and no older than 17 years of age. This is the age the child needs to be at the time they begin the study.
* Are HIV positive.
* Weigh more than 5.5 pounds. A newborn child must have reached at least 38 weeks of gestation.
* Have or have not taken anti-HIV drugs. Those that have not must have a viral load between 5,000 and 500,000 copies/ml at screening. Those that have must have been taking anti-HIV drugs, including lamivudine, for at least 3 months and have a viral load of no more than 400 copies/ml at screening.
* Have a CD4 count of more than 200 cells/mm3.
* Have written consent from parent or guardian.
* Are willing to use effective birth control during the study and for 1 month after the last dose of emtricitabine, if sexually active.

Exclusion Criteria

Children will not be eligible for this study if they:

* Are pregnant or breast-feeding.
* Cannot follow the visit or dosing schedule or are not available for 1 year.
* Have taken experimental drugs or vaccines (except for emivirine and experimental forms of approved drugs) within 30 days of study start.
* Have nerve damage in their arms or legs.
* Have trouble eating or taking drugs.
* Have serious diarrhea within 30 days before study entry.
* Have had any serious illness within 30 days of study screening. Any treatment must have been finished 14 days before study entry.
* Have had an AIDS-related (opportunistic) disease within 12 months of screening.
* Are being treated for tuberculosis.
* Have had pancreatitis.
* Require certain drugs.
Evaluation of the Effects of Home-based Functional Exercise on Patients With ACL

This study will evaluate the effect of home-based functional exercise on patients with anterior cruciate ligament rupture reconstruction based on the health belief model. About 360 participants will be randomly allocated into two groups. One group will randomized to receive precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly, while the other group will randomized to receive the rehabilitation exercise guidance during routine discharge.

With the development of national fitness and sports, the incidence of anterior cruciate ligament (ACL) injuries has increased. ACL reconstruction is the best treatment for ACL injury. The success rate of surgery is high, but the patient still needs to rehabilitate after surgery, otherwise it is difficult to fully recover knee function. However, the rehabilitation medical resources in China are obviously insufficient. Patients who have undergone ACL reconstruction usually return home to work according to the rehabilitation plan. However, the adherence is still poor, and it is difficult to achieve the expected effect. The WeChat public account and its affiliated applets have been widely used in different health fields. The Health Belief Model (HBM) is a guiding theory commonly used in health education to guide patients for behavioral changes. This study aims to use the WeChat small program to explore the effects of optimized the existing Peking University Third Hospital Sports Medicine WeChat small program by using HBM to improve the adherence of patients with home-based functional exercise after ACL injury reconstruction.

Eligibility Criteria:
Inclusion Criteria:

* (1)Age between 18 and 45；
* (2)The first time to do simple ACL reconstruction, may be combined with cartilage -dressing and partial meniscectomy, patients with consistent postoperative rehabilitation plans;
* (3)Having the ability of Basic literacy, communication and accessibility;
* (4)Having a smartphone, using WeChat or can learn to use WeChat.

Exclusion Criteria:

* (1)Having history of joint infection, joint tuberculosis or osteomyelitis, or surgery in the lower extremities within 6 months;
* (2)Being combined with severe heart, brain, kidney and other organ dysfunction;
* (3)Having other serious knee injuries;
* (4)Being with mental illness or cognitive impairment, unable to learn and participate in rehabilitation training;
* (5)Having participated in other similar rehabilitation function training programs, or transferred to other medical institutions after discharge;
* (6)Doing not disagree to participate in the study,and not sign the informed consent.
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.


Eligibility Criteria:
Inclusion Criteria:

* Have Type 2 Diabetes (T2D)
* Have HbA1c ≥ 7.0% to ≤ 9.5%
* Are naïve to insulin therapy and have not used oral or injectable antihyperglycemic (diabetes) medication for at least 90 days prior to screening
* Are of stable weight for at least 90 days prior to screening
* Have a Body Mass Index (BMI) ≥ 23.0 kilograms per meter squared (kg/m\^2)

Exclusion Criteria:

* Have Type 1 Diabetes (T1D)
* Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening
* Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
* Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
* Have an estimated glomerular filtration rate (eGFR) \<15 milliliters/minute/1.73 meter squared (mL/min/1.73 m\^2) as determined by the central laboratory
* Have a prior or planned surgical treatment for obesity
* Have New York Heart Association Functional Classification IV congestive heart failure
* Have had an acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening
* Have a known clinically significant gastric emptying abnormality
* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
* Have any lifetime history of a suicide attempt
* Had chronic or acute pancreatitis
* Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2
* Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening.
A Pilot Randomized Controlled Trial: CoINTEGRATE

The purpose of this study is to examine the feasibility of comprehensive multimodal individually tailored Cognitive Behavioral Therapy (CBT), Cognitive Rehabilitation Therapy (CRT), and modifiable lifestyle sessions.

The study team hypothesizes that combining evidence-based cognitive and affective therapies with lifestyle modifications is feasible and will improve the community integration (CI) and Quality of life (QoL) in patients with a neurocognitive disorder compared to usual care.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with one of the following: Mild Trauma Brain injury (TBI), Multiple Sclerosis (MS), Long COVID, or Mild Cognitive Impairment (MCI)
* MCI patients age older than 50 years old, all other diagnosis 21-65 years old and are receiving care through the Michigan medicine network
* Participants that can provide consent or legally authorized representative who can provide consent on their behalf
* Cognitive impairment ≥ 1.0 standard deviation below the test score normed for age and education in at least 2 cognitive domains (verbal learning and memory, processing speed, or visuospatial memory)

Exclusion Criteria:

* TBI participants symptomatic at rest (headache, dizziness, nausea, or vertigo) will be referred to primary care physician (PCP)
* History of TBI (except for participants with TBI)
* MS participants with recent relapse (1 month prior to enrollment) or on Intravenous or oral steroids
* MCI participants with disease duration greater than 1 year
* Patients with other neurosensory or neurodegenerative diseases
* Diagnosed with COVID-19 (except for Long COVID group)
* Psychiatric disorders other than mild to moderate anxiety and depression
* Patients with severe depression or suicidal (ideation or plan) will be instructed to seek mental health, provided with resources and referred to patient's primary care provider
* Diagnosed sleep disorders
* Visual or auditory impairment,
* Current or history of alcohol or substance abuse/dependence
* Cognitive impairment less than 1.0 standard deviation below the test score normed for age and education in at least 2 cognitive domains (verbal learning and memory, processing speed, or visuospatial memory)
* Cognitive impairment greater or equal to 1.0 standard deviation below the test score normed for age and education in 1 cognitive domain (verbal learning and memory, processing speed, or visuospatial memory)
* Currently receiving CRT, CBT or Occupational therapy (OT) or another type of psychological therapy
Geko™ Plaster Cast Study, Deep Vein Thrombosis (DVT) Prophylaxis

The primary objective of this study is to examine the flow characteristics of deep venous flow in the leg veins using Doppler ultrasound imaging and how this flow is modified by the application of a plaster and with a geko™ device in healthy volunteers


Eligibility Criteria:
Inclusion Criteria:

1. Be in good general health and fitness.
2. Aged between 18 and 65 years.
3. Free of significant abnormal findings as determined by medical history (specifically an absence of DVT or haematological disorders or indications), screening physical examination, vital signs (sitting blood pressure, sitting pulse rate, sitting respiratory rate and body temperature) and duplex ultrasound)
4. BMI between 18 and 34
5. No history or signs of drug abuse (including alcohol), licit or illicit.
6. Has not used any medications (prescribed or over-the-counter including herbal remedies) judged to be significant by the Principal Investigator during the thirty (30) days preceding the study, and agrees not to use any medications during the course of the study without informing the Research Team.
7. Able to understand the Volunteer Information Sheet and signed the written Informed Consent Forms.
8. Able and willing to follow the Protocol requirements.

Exclusion Criteria:

1. Previous leg fracture. (within the last 12 months)
2. Any evidence of organ dysfunction, or any clinically significant deviation from normal in the physical determinations.
3. History or signs of haematological disorders (especially in relation to clotting or coagulation or previous Deep or superficial vein thrombosis/pulmonary embolism) or familiar history of such.
4. Peripheral arterial disease (ABPI\<0.9), clinically significant varicose veins or lower limb ulceration.
5. Musculoskeletal disorders (such as pain during exercise of lower limb, rheumatoid or osteoarthritis).
6. Neurological disorders,(such as stroke, multiple sclerosis)
7. Recent surgery (such as abdominal, gynaecological, hip knee replacement).
8. Recent trauma to lower limbs.
9. Chronic Obesity (BMI Index \>34).
10. Pregnancy.
11. Any Medication judged to be significant by the Principal Investigator.
12. Tobacco consumption
13. History of disorders of the gastrointestinal, hepatic, renal, cardiovascular, endocrine, neurological, dermatological, rheumatologic, metabolic (including diabetes), psychiatric, haematological (especially in relation to clotting or coagulation), or systemic disease judged to be significant.
14. A pulse rate of less than 50 beats/minute, a sitting systolic blood pressure \>160 or \<80 mmHg and/or a sitting diastolic pressure of \>90 or \<60 mmHg.
15. Any significant illness during the four (4) weeks preceding the screening period of the study.
16. Any contraindication to blood sampling.
17. Donation of blood during the eight (8) weeks preceding the screening period of the study or during the investigation.
18. Participation in any clinical study during the 8 weeks preceding the dosing period of the study
19. Fitted with a pacemaker or defibrillator
A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer

This is a prospective pilot study to evaluate the safety and feasibility of neoadjuvant transcatheter infusion and embolism (TACiE) in patients with locally advanced adenocarcinoma of stomach and gastroesophageal junction.

The TACiE protocol includes four cycles. Transcatheter oxaliplatin and concurrent embolism on day 1 and oral S-1 on day 1-14 will be administrated in the first and third cycles. Intra-venous oxaliplatin on day 1 and oral S-1 on day 1-14 (SOX) will be administrated in the second and fourth cycles.


Eligibility Criteria:
Inclusion Criteria:

* Male or female, aged 18 to 75 years old;
* The Karnofsky Performance Scale (KPS) score \>=80;
* Adenocarcinoma of stomach and gastroesophageal junction (Siewert II/III) diagnosed pathologically;
* clinical T3-4a/N+/M0 (The 8th edition of the American Joint Committee on Cancer (AJCC) staging system);
* According to the Response Evaluation Criteria In Solid Tumours (RECIST) 1.1 standard, there is at least one evaluable lesion in the abdominal CT/MRI;
* The surgeons participating in this study judged the lesion to be resectable;
* Physical condition allows the surgery;

Exclusion Criteria:

* Distant metastasis or local unresectable factors;
* Cytotoxic chemotherapy, radiotherapy, immunotherapy or radical surgery for the treatment of this gastric cancer, except for corticosteroids;
* Active autoimmune diseases or a history of autoimmune diseases;
* History of malignant tumors within 2 years;
* Gastrointestinal bleeding within two weeks prior to enrollment, or those with high bleeding risk;
* Gastrointestinal perforation and/or fistula occurred within 6 months before enrollment;
* Upper gastrointestinal obstruction or abnormal physiological function or suffering from malabsorption syndrome, which may affect the absorption of drugs;
* Weight loss \>=20% within 2 months before enrollment;
* A history of the following lung diseases: interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, acute lung disease, etc.;
* Uncontrollable systemic diseases including diabetes, hypertension, etc.; Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis, HIV infection, etc.;
* Untreated patients with chronic hepatitis B or chronic HBV carriers with hepatitis B virus (HBV) DNA exceeding 500 IU/mL, or hepatitis C virus (HCV) RNA positive patients should be excluded;
* Any of the following cardiovascular risk factors (refer to Research Guide);
* Known peripheral nerve disease \>=NCI CTCAE Grade 1. However, patients with only the disappearance of the deep tendon reflex (DTR) need not be excluded;
* Moderate or severe renal damage \[creatinine clearance equal to or lower than 50 ml/min (calculated according to the Cockcroft and Gault equation)\], or serum creatinine\> upper limit of normal (ULN); People with known dihydropyrimidine dehydrogenase (DPD) deficiency;
* Those who are allergic to any research drug ingredients;
* Underwent major surgery within 28 days prior to enrollment;
Study of Inherited Changes of Receptors Located on Blood Vessels

The renin angiotensin system is a complex process involving hormones and enzymes that regulate blood volume and blood pressure. The hormone angiotensin II is responsible for making blood vessels narrow or constrict. Angiotensin II is found in the blood and can attach to special sites called receptors on blood vessel walls. These receptors are programmed to accept angiotensin II and cause a constriction of the blood vessel. This function is found in the genetic information of each individual person.

Occasionally patients have changes in their genes related to angiotensin II receptors. These changes may result in the receptors acting differently to angiotensin II, which may affect the function of blood vessels.

This study is designed to improve researchers understanding of the physiological effects on blood vessels associated with mutations of the genes responsible for angiotensin II receptor function.

Polymorphisms in the genes encoding for various elements of the renin angiotensin system have been associated with cardiovascular disease. We have isolated novel alleles in the angiotensin II type I receptor gene. We propose this exploratory investigation to study the physiological effect of these mutations on vascular function in patients and family members who carry these rare alleles.

Eligibility Criteria:
Patients aged 21 or older with chronic orthostatic intolerance will be included.

There will be no exclusion from participation in the study on the basis of ethnicity/race.

Patients will be recruited in the Cardiology Branch outpatient clinic, Dr. David Goldstein (Chief Neurocardiology Section, NINDS, NIH), or from outside physicians.

Children will be excluded from the study because of inability in obtaining informed consent.

Cognitively impaired individuals, prisoners, or other institutionalized persons will not be able to participate.
The Effect of Topical Curcumin Versus Topical Corticosteroid on Management of Oral Lichen Planus Patients

Introduce a new anti-inflammatory and antioxidant paste preparation (curcumin paste) in the management of Oral lichen planus.

* Assess the efficacy of this preparation on pain, clinical parameter and the level of IL-33 in saliva.
* Compare the outcome of new preparation with the gold standard treatment (corticosteroids).

Two groups will be prepared then decision of which one take curcumin paste will be selected according to randomized numbers in a sequentially numbered, opaque, sealed envelope

1 group will take topical corticosteroid and 1 will take curcumin paste then IL-33 level in saliva will be measured at the base line and at the end of 4th week pain and clinical parameters will be measured at 2nd and 4th week

Eligibility Criteria:
Inclusion Criteria:

* Patients who will be clinically diagnosed as having atrophic \&/or erosive oral lichen planus.
* Patients with controlled diabetes and/or controlled hypertension will be included in the study.
* Patients with no history of taking corticosteroids for the last 6 months
* Patients who agrees to take medication.

Exclusion Criteria:

* Pregnant and lactating ladies.
* Patients with history of topical steroids during last 2 months \& systemic steroids during last 6 months.
* Patients with recent dental filling associated with the lesion or associated with recent drug administration.
* Patient with uncontrolled diabetes, uncontrolled hypertension, or those with positive HCV ab or HBs Ag.
Physical Therapy Interventions Following Arthroscopic Rotator Cuff Repair

In the post-arthroscopic rotator cuff repair (ARCR) management, physical therapy intervention is an important factor in bringing about a clinically positive prognosis. However, no conclusive therapeutic evidence has been found for various physical therapy interventions. In this study, the investigators would like to investigate the effects of physical therapy interventions on ARCR patients.


Eligibility Criteria:
Inclusion Criteria:

* Adults over 18 years old
* In case of 2 weeks after receiving arthroscopic rotator cuff repair
* When the participants wishes to enroll in the study

Exclusion Criteria:

* 65 years old or older
* If the tear area is large and augmentation is performed
* If there is a previous surgical history at the surgical site
* Osteoarthritis in the shoulder joint